Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Abbott Laboratories (Pakistan)'s quarterly Ending Cash Position
increased
from Sep. 2025 (₨9,010 Mil) to Dec. 2025 (₨13,338 Mil) but then
declined
from Dec. 2025 (₨13,338 Mil) to Mar. 2026 (₨12,473 Mil).
Abbott Laboratories (Pakistan)'s annual Ending Cash Position
increased
from Dec. 2023 (₨5,037 Mil) to Dec. 2024 (₨6,182 Mil) and
increased
from Dec. 2024 (₨6,182 Mil) to Dec. 2025 (₨13,338 Mil).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abbott Laboratories (Pakistan) Ending Cash Position Chart
Abbott Laboratories (Pakistan) Ending Cash Position Calculation
Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.
What does a Ending Cash Position of ₨12,473 Mil mean?
Abbott Laboratories (Pakistan) (KAR:ABOT) has a Ending Cash Position of ₨12,473 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Abbott Laboratories (Pakistan) and its competitors.
Is Abbott Laboratories (Pakistan)'s Ending Cash Position too high?
Abbott Laboratories (Pakistan)'s current Ending Cash Position is ₨12,473 Mil. Overall, Abbott Laboratories (Pakistan) has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Abbott Laboratories (Pakistan)'s Ending Cash Position compare to ZTS and UTHR?
Abbott Laboratories (Pakistan)'s Ending Cash Position of ₨12,473 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Abbott Laboratories (Pakistan) and its competitors. Abbott Laboratories (Pakistan)'s current Ending Cash Position is ₨12,473 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abbott Laboratories (Pakistan) stock overvalued right now?
Based on GuruFocus' analysis, Abbott Laboratories (Pakistan) (KAR:ABOT) is currently considered Modestly Undervalued. The stock's GF Value™ is ₨1,025.11, compared to a current price of ₨911.28 — trading 11.1% below its estimated fair value. The current Ending Cash Position is ₨12,473 Mil. Abbott Laboratories (Pakistan)'s overall GF Score™ is 71/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Abbott Laboratories (Pakistan) (KAR:ABOT), the current Ending Cash Position is ₨12,473 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abbott Laboratories (Pakistan) (KAR:ABOT) Overvalued in 2026?
Based on GuruFocus' analysis, Abbott Laboratories (Pakistan) stock appears to be undervalued.
The current stock price of ₨911.28 is trading 11.1% below its estimated GF Value™ of ₨1,025.11.
GuruFocus considers Abbott Laboratories (Pakistan) to be Modestly Undervalued.
Key valuation signals for KAR:ABOT:
Ending Cash Position: ₨12,473 Mil
GF Value™: ₨1,025.11 vs. price of ₨911.28 (11.1% below fair value)
No single metric tells the full story. See the KAR:ABOT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abbott Laboratories (Pakistan) Ltd manufactures, imports, and markets research-based pharmaceutical, nutritional, diagnostic, diabetes care, molecular devices, hospital, and consumer products. Its operating segments are Pharmaceutical, Nutritional, Diagnostics, and Others. It generates maximum revenue from the Pharmaceutical segment. Geographically, it derives the majority of its revenue from Pakistan and has a presence in Afghanistan, Sri Lanka, Bangladesh, and Switzerland. The company's Brands include Duphaston, Brufen, Surbex Z, Arinac, Glucerna, Pediasure, and Ensure.
71GF Score
Get the complete analysis for KAR:ABOT
Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAR:ABOT has been successfully added to your 
